TEK antibody, DKFZp469E064 antibody, AA517024 antibody, Cd202b antibody, Hyk antibody, Tie2 antibody, tie-2 antibody, CD202B antibody, TIE-2 antibody, TIE2 antibody, VMCM antibody, VMCM1 antibody, Tie-2 antibody, tie2 antibody, TEK receptor tyrosine kinase antibody, angiopoietin-1 receptor antibody, TEK tyrosine kinase, endothelial antibody, TEK antibody, LOC100408334 antibody, tek antibody, Tek antibody
Background
TIE-2 acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. It has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. It is required for normal angiogenesis and heart development during embryogenesis and for post-natal hematopoiesis. After birth, it activates or inhibits angiogenesis, depending on the context. It inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1 and ultimately to the stimulation of sprouting angiogenesis.